8 results about "Melanocortin" patented technology

The description refers to a method for treating a disease or disorder in a subject by using a combination of: (i) a potassium channel activator (e.g., a SURx / Kirx channel activating compound) or a pharmaceutically acceptable salt thereof; and (ii) a melanocortin-4 receptor (MC4R) agonist.

The present disclosure relates to the use of a compound of chemical Formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing, improving, or treating a genetic obesity disease associated with the melanocortin-4 receptor (MC4R) pathway, particularly a genetic obesity disease associated with SH2B1 deficiency or a LEPR deficiency.

The disclosure herein provides a compound of formula (1): JPEG2026507093000332.jpg3670 or a salt thereof (wherein J, X, Z, L 1 , L 2 , R 1 , R 2 , R 3 , R 3a , R 3b , R 3c and R 4 The present invention relates to their use in the treatment, prevention, amelioration, suppression, or reduction of the risk of disorders associated with the melanocortin subtype-2 receptor (MC2R) (as defined herein) and the melanocortin subtype-2 receptor (MC2R).

The disclosures herein relate to compounds of Formula (1) and (2): (1); (2); or a pharmaceutically acceptable salt thereof and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with the melanocortin subtype-2 receptor (MC2R).

Provided herein are stable aqueous pharmaceutical compositions and formulation comprising non-naturally occurring melanocortin agonist analogs. The non-naturally occurring melanocortin agonist analog comprises a sequence of Formula (I): Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 2), wherein c represents cyclization via a lactam bond.

Provided herein are pharmaceutical compositions of non-naturally occurring melanocortin agonist analogs formulated for oral administration. The non-naturally occurring melanocortin agonist analog comprises a sequence of Formula (I): Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 2), wherein c represents cyclization via a lactam bond.

The disclosures herein relate to pharmaceutically acceptable salts of a compound of Formula (1) and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with the melanocortin subtype-2 receptor (MC2R).

The disclosures herein relate to pharmaceutical compositions comprising a compound of Formula (1): (1); or a pharmaceutically acceptable salt thereof and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with the melanocortin subtype-2 receptor (MC2R).